How Hospice Agencies Are Valued
Hospice has become one of the most active and richly-multiple healthcare M&A segments. The combination of demographic tailwinds (aging boomers), capitated Medicare reimbursement, predictable margins, and PE-platform consolidation pressure has driven multiples to 9-12.5x EBITDA — meaningfully higher than home health (typically 6-9x) or skilled nursing (4-7x).
What follows is the band-by-band breakdown buyers actually use, and the specific operational metrics that move you within your band.
Average Daily Census: The Single Most-Watched Metric
Average Daily Census (ADC) — the average number of patients on service per day — is the metric buyers anchor every other calculation to. The rough rule of thumb in 2026: $50-90K of transaction value per ADC, depending on operational quality, geographic exclusivity, and length of stay.
A hospice with 200 ADC trading at $70K/ADC = $14M transaction value. Buyers will overlay EBITDA-based valuation as a cross-check, but the per-ADC anchor is how the deal gets initially structured. Strong operations push toward $80-90K/ADC; problematic operations (high turnover, compliance issues, short LOS) drop to $40-60K.
Length of Stay: The Profitability Lever
Medicare hospice reimbursement is per-diem, but the cost curve is front-loaded — admissions, initial assessments, and stabilization are the most expensive days. Hospices with longer median length of stay (LOS) generate more profitable patient-days and trade at premium multiples.
Median LOS by service line:
- 15-30 days median LOS: short-stay hospice (often hospital-system referral-heavy). Lower margin per patient.
- 30-60 days median LOS: balanced book. Industry-standard profitability.
- 60-90+ days median LOS: long-stay book (often community-based / Alzheimer's / complex chronic). Premium profitability and premium multiples.
However: very long LOS (especially 180+ days) can trigger CMS audit attention. Buyers diligence this carefully — high margin from very long LOS plus weak documentation = audit risk = deal discount.
Payor Mix and Cap Compliance
Medicare typically represents 80-95% of hospice revenue. Medicaid, commercial insurance, and private pay round out the rest. Multi-payor balance is healthy but not heavily rewarded.
Hospice cap compliance is the make-or-break item in diligence. CMS imposes an annual aggregate cap on per-beneficiary Medicare reimbursement; hospices that exceed the cap repay the overage. Hospices with multi-year cap-compliance records command premium multiples; hospices with cap exposure or active repayment obligations trade at significant discount.
Geographic Coverage and Acquisition Strategy
Buyers are typically building geographic platforms — assembling multiple agencies in a region for shared back-office, referral efficiency, and CON (Certificate of Need) leverage in CON states. A hospice in a state where new licenses are difficult or impossible to obtain trades at a meaningful premium because the asset is irreplaceable.
CON states: NC, NY, VA, GA, MS, LA, KY, WV, SC, MD, AL, TN, IL all have hospice CON requirements that limit new market entry. Existing licenses in these states command premium multiples.
What Drives Premium Multiples
Multi-year ADC growth: stable or expanding ADC over 36 months signals operational health and referral relationship depth.
Quality scores: CAHPS (Consumer Assessment of Healthcare Providers and Systems) Hospice scores, Hospice Compare star ratings. Top-quartile scores command premium because buyers can underwrite continued referral flow.
Referral source diversification: hospices with 3-5 major referral sources (multiple hospital systems, multiple SNF networks, multiple physician groups) trade higher than hospices dependent on a single referral source.
In-house pharmacy and DME: vertical integration of pharmacy and durable medical equipment adds margin and operational control. Buyers value this both for the margin and for the strategic difficulty of replicating it.
What Reduces Hospice Valuations
OIG audit history or open investigations: any Office of Inspector General audit activity, settled or pending, creates significant deal complexity. Buyers will discount and may structure escrows or indemnities to address.
High live discharge rate: patients discharged alive from hospice (graduated off service) above industry norm raises CMS scrutiny. Buyers diligence this and discount accordingly.
Survey deficiencies: state survey deficiencies, especially condition-level findings, create deal risk. Recent clean survey history is an underwriting checkmark.
Single-source referral concentration: a hospice getting 50%+ of admissions from one hospital system is one referral-relationship change away from material revenue loss. Trade at meaningful discount.
Who Buys Hospice Right Now
Strategic public chains — Addus HomeCare (ADUS), Enhabit (EHAB), Encompass Health (EHC), Humana CenterWell, Bristol Hospice, Compassus — actively acquire mid-size and platform hospices.
PE-backed platforms — Webster Equity (Bristol), BlueMountain (multiple), Roundtable Healthcare, Charlesbank — buy for roll-up. Multi-state platforms typically trade at premium to single-state platforms.
Hospital systems — increasingly acquiring hospice for continuum-of-care and referral capture. Tend to pay slightly less than PE / strategic but offer cleaner exits.